Advances in gene therapy delivery: next-generation transfection reagent for large-scale AAV manufacturing
The number of ATMP therapeutic-based medicines for inherited genetic disorders is in constant growth, with a global 32% increase in new clinical trials in the last 4 years. ATMPs have demonstrated their success with already more than ten approved for commercialization.
Attendees will learn:
Attendees will learn:
- How to improve AAV viral vector yields by focusing on transfection step.
- How to perform transfection at large scale.
- How to ensure reproducibility at different production scales.